Canadian drugmaker Valeant Pharmaceuticals International Inc VRX.TO VRX.N raised the cash component of its unsolicited offer for Botox-maker Allergan Inc AGN.N, but the increased bid fell short of expectations and the stock of both companies fell.
Hospital operator Kindred Healthcare Inc went hostile with a $533 million offer for Gentiva Health Services Inc , after the home healthcare services provider rejected the bid saying it could generate more value as a standalone company.
Forest Laboratories Inc said it would buy Furiex Pharmaceuticals Inc for up to $1.46 billion, including milestone payments, to add a promising treatment for irritable bowel syndrome to its gastrointestinal drugs portfolio.
Zimmer Holdings Inc said on Thursday it would buy rival orthopaedic products maker Biomet Inc for more than $13 billion (£7,736,713,682.08), the latest deal in a wave of consolidations in the healthcare industry.
Zimmer Holdings Inc said on Thursday it would buy rival orthopedic products maker Biomet Inc for more than $13 billion, the latest deal in a wave of consolidations in the healthcare industry.
The U.S. Food and Drug Administration on Tuesday proposed speeding up medical device approvals for patients who have no other treatment options through a new program focused on earlier and more frequent interactions between companies and FDA staff.
Sarepta Therapeutics Inc's shares soared 64 percent after it said that the U.S. Food and Drug Administration indicated an alternate path to approval for the company's experimental muscle disorder drug.
Specialty pharmaceuticals company Mallinckrodt Plc will buy drugmaker Questcor Pharmaceuticals Inc for about $5.6 billion to gain access to its multiple sclerosis drug, Acthar Gel, which is set to hit sales of $1 billion this year.
Generic injectable drugs maker Sagent Pharmaceuticals Inc is looking to shore up its portfolio with deals worth up to $500 million, as rampant manufacturing issues and quality concerns push consolidation in the industry.
An experimental cancer drug developed by Eli Lilly and Co, touted by some to be the company's next blockbuster, significantly improved survival rates in lung cancer patients, sending the company's shares up 3 percent in early trading.